The importance of measuring quality of life in phase I/II trials of cancer therapy--the effects of antibody targeted therapy: Part I.

European journal of cancer care

Volumn 6, Issue 4, 1997, Pages 267-272

  Hope Stone, L D ^a   Napier, M P ^a   Begent, R H ^a   Cushen, N ^a   O'Malley, D ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; MONOCLONAL ANTIBODY;

ADULT; AGED; ANXIETY; ARTICLE; CLINICAL TRIAL; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; FEMALE; HUMAN; MALE; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RADIOIMMUNOTHERAPY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANXIETY; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; COLORECTAL NEOPLASMS; DEPRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; RADIOIMMUNOTHERAPY;

EID: 0031304090     PISSN: 09615423     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2354.1997.00053.x     Document Type: Article

References (0)